Market Overview

UPDATE: Deutsche Bank Initiates Coverage on Alnylam Pharmaceuticals with Buy Rating, $40 PT on Significant Long-Term Value Potential

Share:
Related ALNY
Credit Suisse Bullish On Most Big Pharma Names
Alnylam Pharmaceuticals Dips Lower After Company Announces 2016 Pipeline Goals Towards 'Alnylam 2020'
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2015 Results - Earnings Call Transcript (Seeking Alpha)

In a report published Friday, Deutsche Bank analyst Alethia Young initiated coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Buy rating and $40.00 price target.

In the report, Young noted, “Alnylam is an early stage company that uses a technology called RNA interference that occurs naturally in the body to silence problematic genes in diseases that were previously deemed un-druggable. We believe Alnylam has the chance to unlock significant long-term value as they commercialize their assets in the clinic during 2017 and beyond, leading to $4B+ in unadjusted sales. We initiate with a Buy rating and a $40 target price.”

Alnylam Pharmaceuticals closed on Thursday at $28.06.

Latest Ratings for ALNY

DateFirmActionFromTo
Jan 2016Credit SuisseInitiates Coverage onOutperform
Nov 2015Leerink SwannMaintainsOutperform
Oct 2015JefferiesInitiates Coverage onBuy

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Initiation Analyst Ratings

 

Related Articles (ALNY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters